Beam Therapeutics (BEAM) Debt to Equity (2019 - 2025)
Historic Debt to Equity for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $0.01.
- Beam Therapeutics' Debt to Equity fell 3661.21% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year decrease of 3661.21%. This contributed to the annual value of $0.01 for FY2024, which is 405.03% up from last year.
- According to the latest figures from Q3 2025, Beam Therapeutics' Debt to Equity is $0.01, which was down 3661.21% from $0.0 recorded in Q2 2025.
- Over the past 5 years, Beam Therapeutics' Debt to Equity peaked at $0.17 during Q1 2021, and registered a low of $0.0 during Q2 2025.
- Moreover, its 5-year median value for Debt to Equity was $0.02 (2023), whereas its average is $0.04.
- In the last 5 years, Beam Therapeutics' Debt to Equity soared by 33079.43% in 2021 and then plummeted by 8683.49% in 2022.
- Over the past 5 years, Beam Therapeutics' Debt to Equity (Quarter) stood at $0.05 in 2021, then plummeted by 51.12% to $0.02 in 2022, then plummeted by 55.89% to $0.01 in 2023, then increased by 4.05% to $0.01 in 2024, then crashed by 41.24% to $0.01 in 2025.
- Its Debt to Equity stands at $0.01 for Q3 2025, versus $0.0 for Q2 2025 and $0.0 for Q1 2025.